IPCA Laboratories Limited

Price Chart

Risk-Adjusted Performance

IPCA Laboratories Limited (IPCALAB) Price Performance

IPCA Laboratories Limited (IPCALAB) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR1468.30, up 0.47% from the previous close.

Over the past year, IPCALAB has traded between a low of INR1268.70 and a high of INR1601.20. The stock has gained 5.5% over this period. It is currently 8.3% below its 52-week high.

IPCA Laboratories Limited has a market capitalization of $372.11B, with a price-to-earnings ratio of 40.72 and a dividend yield of 0.14%.

About IPCA Laboratories Limited

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.